Page 154 - IJB-8-2

Laser printing of Gemcitabine on microneedles
25. Haj-Ahmad R, Khan H, Arshad MS, et al., 2015, Microneedle 33. Skavatsou E, Semitekolou M, Morianos I, et al., 2021.
Coating Techniques for Transdermal Drug Delivery. Immunotherapy Combined with Metronomic Dosing: An
Pharmaceutics, 7:486–502. Effective Approach for the Treatment of NSCLC. Cancers
https://doi.org/10.3390/pharmaceutics7040486 (Basel), 13:1901.
26. Papazoglou S, Zergioti I, 2017, Laser Induced Forward https://doi.org/10.3390/cancers13081901
Transfer (LIFT) of nano-micro patterns for sensor 34. Infante JR, Benhadji KA, Dy GK, et al., 2015. Phase 1b
applications. Microelectron Eng Rev, 182:25–34. Study of the Oral Gemcitabine “Pro-drug” LY2334737 in
27. Paroha S, Verma J, Dubey RD, et al., 2021, Recent Advances Combination with Capecitabine in Patients with Advanced
and Prospects in Gemcitabine Drug Delivery Systems. Int J Solid Tumors. Invest New Drugs, 33:432–9.
Pharm, 592:120043. https://doi.org/10.1007/s10637-015-0207-9
https://doi.org/10.1016/j.ijpharm.2020.120043 35. Kanaki Z, Voutsina A, Markou A, et al., 2021, Generation of
28. Reid JM, Qu W, Safgren SL, et al., 2004. Phase I Trial and Non-Small Cell Lung Cancer Patient-Derived Xenografts to
Pharmacokinetics of Gemcitabine in Children with Advanced Study Intratumor Heterogeneity. Cancers (Basel), 13:2446.
Solid Tumors. J Clin Oncol, 22:2445–51. https://doi.org/10.3390/cancers13102446
https://doi.org/10.1200/jco.2004.10.142 36. Wang W, Chrisey DB, 2008, Study of Impact-Induced
29. Bhatnagar S, Kumari P, Pattarabhiran SP, et al., 2018, Zein Mechanical Effects in Cell Direct. J Manuf Sci Eng,
Microneedles for Localized Delivery of Chemotherapeutic 130:1–10.
Agents to Treat Breast Cancer: Drug Loading, Release 37. Theodorakos I, Kalaitzis A, Makrygianni M, et al., 2019,
Behavior, and Skin Permeation Studies. AAPS PharmSciTech, Laser-induced forward transfer of high viscous, non-
19:1818–26. newtonian silver nanoparticle inks: Jet dynamics and
https://doi.org/10.1208/s12249-018-1004-5 temporal evolution of the printed droplet study. Adv Eng
30. Karampelas T, Argyros O, Sayyad N, et al., 2014. GnRH- Mater, 21:1900605.
Gemcitabine Conjugates for the Treatment of Androgen- https://doi.org/10.1002/adem.201900605
independent Prostate Cancer: Pharmacokinetic Enhancements 38. Makrygianni M, Millionis A, Kryou C, et al., 2018, On-
Combined with Targeted Drug Delivery. Bioconjug Chem, Demand Laser Printing of Picoliter-Sized, Highly Viscous,
25:813–23. Adhesive Fluids: Beyond Inkjet Limitations. Adv Mater
https://doi: 10.1021/bc500081g Interfaces, 5:1800440.
31. Karampelas T, Skavatsou E, Argyros O, et al., 2017. https://doi.org/10.1002/admi.201800440
Gemcitabine Based Peptide Conjugate with Improved 39. Pratt SE, Durland-Busbice S, Shepard RL, et al., 2013.
Metabolic Properties and Dual Mode of Efficacy. Mol Pharm, Efficacy of Low-dose Oral Metronomic Dosing of the Prodrug
14:674–85. of Gemcitabine, LY2334737, in Human Tumor Xenografts.
https://doi.org/10.1021/acs.molpharmaceut.6b00961 Mol Cancer Ther, 12:481–90.
32. Sayyad N, Vrettos EI, Karampelas T, et al., 2019. https://doi.org/10.1158/1535-7163.MCT-12-0654
Development of Bioactive Gemcitabine-D-Lys6-GnRH 40. Veltkamp SA, Jansen RS, Callies S, et al, 2008. Oral
Prodrugs with Linker-controllable Drug Release Rate and Administration of Gemcitabine in Patients with Refractory
Enhanced Biopharmaceutical Profile. Eur J Med Chem, Tumors: A Clinical and Pharmacologic Study. Clin Cancer
166:256–66. Res, 14:3477–86.
https://doi:10.1016/j.ejmech.2019.01.041 https://doi.org/10.1158/1078-0432.CCR-07-4521

Publisher’s note
Whioce Publishing remains neutral with regard to
jurisdictional claims in published maps and institutional
affiliations.

146 International Journal of Bioprinting (2022)–Volume 8, Issue 3